Business / Finance

RSS

NGAGE signs five-year representation deal with SIEMENS Healthcare

NGAGE US LLC today announced the signing of a five-year representation agreement with SIEMENS Healthcare of Malvern, PA. Under the agreement, NGAGE will complement the direct sales force of SIEMENS by deploying teams of sales executives in selected products and geographies. NGAGE will focus on two market segments: Women's Health and Diagnostic Imaging in targeted growth areas.

13 Nov 2013

immatics, Roche enter into cancer vaccine and immunotherapy deal

immatics biotechnologies GmbH and Roche today announced a strategic research and development collaboration covering multiple cancer vaccines and immunotherapeutics.

13 Nov 2013

HealthSouth enters into privately negotiated exchange agreements

HealthSouth Corporation (NYSE: HLS) today announced that the Company entered into separate, privately negotiated exchange agreements under which it will issue $320 million in aggregate principal amount of new 2.0% Convertible Senior Subordinated Notes due 2043 in exchange for 257,110 shares of the Company's outstanding 6.5% Series A Convertible Perpetual Preferred Stock, par value $0.10 per share.

13 Nov 2013

Merck Serono signs co-development and commercialization agreement for BeiGene-290

Merck Serono, the biopharmaceutical division of Merck, today announced that a global licensing, co-development, and commercialization agreement for BeiGene-290 has been signed with BeiGene Co., Ltd., a biotech research and development company in Beijing, China.

13 Nov 2013

Orexigen Therapeutics reports net loss of $18.6 million in Q3 2013

Orexigen Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced business and financial results for the third quarter ended September 30, 2013.

12 Nov 2013

S2O2 finalizes acquisition of Texas-based sanitation technology innovator

Neutra Corp., a growing provider of all-natural wellness solutions, announced today that its joint venture partner Surface to Air Solutions is finalizing the acquisition of a sanitation technology innovator dedicated to greatly reducing the risk of staph infection in sports.

12 Nov 2013

BioGaia plans to invest in first phase of project aimed at developing drug for NEC

The board of BioGaia has decided to invest in the first phase of a long-term project aimed at developing a drug with rigorous hygiene, analysis and documentation requirements, to treat the highly fatal disease Necrotising Enterocolitis, which affects premature infants.

12 Nov 2013

Helsinn grants exclusive commercialization rights to Chugai Pharma Marketing for anamorelin drug

Swiss-based Helsinn group has granted Chugai Pharma Marketing Ltd., a wholly-owned subsidiary of Chugai Pharmaceutical Co., Ltd., exclusive commercialization rights to their innovative ghrelin receptor agonist, anamorelin, for the three major European pharma markets.

12 Nov 2013

IEEE-SA, Continua partner to broaden adoption of standards-based technologies for healthcare arena

IEEE Standards Association and Continua Health Alliance today announced they have signed a strategic agreement to help accelerate and broaden the adoption of globally relevant standards-based technologies for the healthcare arena.

12 Nov 2013

Delmar Pharmaceuticals announces quarterly update, strengthens intellectual property portfolio

As of September 30, 2013, Delmar Pharmaceuticals has cash and equivalents of approximately $5.2 million and its working capital balance is in line with its expectations.

11 Nov 2013

ERBA Diagnostics’ net revenues increase 83% to $6,941,000 in third quarter 2013

ERBA Diagnostics, Inc., a fully integrated in vitro diagnostics company, reported its financial results for the three and nine months ended September 30, 2013.

11 Nov 2013

Cardioinsight completes long-term strategic financing to conclude multi-center clinical studies in Europe

CardioInsight Technologies, Inc., a leading developer of non-invasive electrocardiographic mapping technology, announced today that it has completed a long-term strategic financing that provides the Company with an initial investment of $15 million.

11 Nov 2013

Chindex International third quarter 2013 revenue increases 16% to $43.1 million

Chindex International, Inc., an American healthcare company providing healthcare services in China through the operations of United Family Healthcare, a network of private primary care hospitals and affiliated ambulatory clinics, today announced financial results for the third quarter of 2013 ended September 30, 2013.

11 Nov 2013

Lawnwood Regional Medical Center & Heart Institute buys first Renaissance system

Mazor Robotics Ltd., the developer of Renaissance, an innovative surgical guidance system and its complementary products, announced today that Lawnwood Regional Medical Center & Heart Institute, located in Ft. Pierce, FL, has purchased its first Renaissance system.

11 Nov 2013

ChinaSoft inks agreement with CITIC 21CN on Pharmaceutical Information Sharing Program

ChinaSoft International Limited, announced that it has signed a strategic agreement with CITIC 21CN Company Limited on the Pharmaceutical Information Sharing Program.

11 Nov 2013

Genovate, ScinoPharm to jointly develop new-generation oral Hepatitis B drug Livepro

Genovate Biotechnology Co. Ltd. and ScinoPharm Taiwan Ltd. announced today that they have jointly developed the highly potent oral generic drug Livepro (Entecavir), representing a new generation of drugs for the treatment of Hepatitis B. It is expected to be commercially available by the end of the year in Taiwan, accounting for more than NT$2 billion (US$70 million) worth of market opportunity.

11 Nov 2013

Covidien fourth quarter net sales increase 2% to $2.56 billion

Covidien plc today reported results for the fourth quarter of fiscal 2013 (July - September 2013). Fourth-quarter net sales of $2.56 billion increased 2% from the $2.50 billion in the fourth quarter a year ago. Foreign exchange rate movement lowered the quarterly sales growth rate by three percentage points.

8 Nov 2013

China Cord Blood Corporation releases financial results for second quarter and first half of fiscal year 2014

China Cord Blood Corporation (NYSE: CO) (the "Company") today announced its plan to release financial results for the second quarter and first half of fiscal year 2014 on Thursday, November 14, 2013, after market close in the US.

7 Nov 2013

ImmunGene secures $9 million in Series A financing from Ally Bridge Group

ImmunGene, Inc., a biotechnology company focused on developing antibody-cytokine fusion technology therapies to treat cancer, today announced it has secured $9 million in a milestone-based Series A financing from Ally Bridge Group. Previous investments in the Company were converted into Series A preferred stock. ImmunGene will use the capital to advance its early-stage development products to IND-enabling studies.

7 Nov 2013

Immunocore achieves first milestone in major research and licensing agreement with GSK

Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs to treat cancer and viral disease, today announced the achievement of its first milestone in its major research and licensing agreement with GlaxoSmithKline for multiple novel targets.

7 Nov 2013

Business / Finance

NGAGE signs five-year representation deal with SIEMENS Healthcare

immatics, Roche enter into cancer vaccine and immunotherapy deal

HealthSouth enters into privately negotiated exchange agreements

Merck Serono signs co-development and commercialization agreement for BeiGene-290

Orexigen Therapeutics reports net loss of $18.6 million in Q3 2013

S2O2 finalizes acquisition of Texas-based sanitation technology innovator

BioGaia plans to invest in first phase of project aimed at developing drug for NEC

Helsinn grants exclusive commercialization rights to Chugai Pharma Marketing for anamorelin drug

IEEE-SA, Continua partner to broaden adoption of standards-based technologies for healthcare arena

Delmar Pharmaceuticals announces quarterly update, strengthens intellectual property portfolio

ERBA Diagnostics’ net revenues increase 83% to $6,941,000 in third quarter 2013

Cardioinsight completes long-term strategic financing to conclude multi-center clinical studies in Europe

Chindex International third quarter 2013 revenue increases 16% to $43.1 million

Lawnwood Regional Medical Center & Heart Institute buys first Renaissance system

ChinaSoft inks agreement with CITIC 21CN on Pharmaceutical Information Sharing Program

Genovate, ScinoPharm to jointly develop new-generation oral Hepatitis B drug Livepro

Covidien fourth quarter net sales increase 2% to $2.56 billion

China Cord Blood Corporation releases financial results for second quarter and first half of fiscal year 2014

ImmunGene secures $9 million in Series A financing from Ally Bridge Group

Immunocore achieves first milestone in major research and licensing agreement with GSK

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Latest News